Answers to your questions about medical liability related to the COVID-19 public health emergency.
Other content in this Stream

CME: Adult preventative care during COVID-19; Remote patient monitoring; Failure to communicate and to properly administer warfarin; Retained foreign body and alteration of medical record

Clearly communicate your office mask policies to patients

Use this sample message to explain your COVID-19 mask policy

TMLT risk managers urge physicians to stay up-to-date on COVID-19 vaccination information.

How to defuse tense or angry situations in the office

State requirements for chronic pain patients have been suspended by Governor Abbott until May 1, 2021

New HHS rule narrowly expands telemedicine across state lines for “COVID-19 countermeasures.”

While both the physician and patient have the right to terminate the relationship, the requirements for ending the relationship are more complicated for physicians.

Resources for practices on appropriate quarantine, infection control measures, and safe return to work protocols.

The Texas Medical Board (TMB) has issued a statement to update physicians on the TMB’s response to the COVID-19 public health emergency.

TMA releases updated FAQ on COVID-19 testing information

As COVID-19 stay-at-home orders relax, practices are re-opening and must now follow new safety standards and guidelines.

Updated May 11 — Issues include encouraging social distancing and screening patients for symptoms.

Adopting COVID-19 to your informed consent process.

Best practices to communicate with patients and families during COVID-19.

Explore the implications and solutions for stress and burnout in a health care setting, including how the COVID-19 pandemic is affecting our community.

Explore how to optimize your virtual office for telehealth visits with patients.

A discussion of risk management recommendations for physicians as they continue to practice during COVID-19. Topics include encouraging social distancing and screening patients.

New dividend will save policyholders $13 million in premium.

TMB urges caution around questionable COVID-19 treatments